| Alexandria Mickenzie Betz, | |
|
887 Congress St Ste 200, Portland, ME 04102-3166 | |
| (207) 771-5549 | |
| Not Available |
| Full Name | Alexandria Mickenzie Betz |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 13 Years |
| Location | 887 Congress St Ste 200, Portland, Maine |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538458377 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Maine Medical Center | Portland, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Eastern Maine Medical Center | 2062315161 | 577 |
| Maine Medical Partners | 9335043967 | 789 |
| Mainehealth | 7517860588 | 2067 |
| St Marys Regional Medical Center | 0042107120 | 203 |
News Archive
A public-private consortium led by the biotech Iproteos -based at Parc Científic de Barcelona (PCB)-, and comprised by the biopharmaceutical company Ascil-Biopharma, the Institute for Biomedical Research (IRB Barcelona), the Centre for Genomic Regulation (CRG) and the University of the Basque Country (UPV/EHU) has launched a project to advance the development of a new neuroprotective drug for the treatment of the cognitive impairment associated with schizophrenia and other mental disorders.
The prescribed use of stimulant medications to treat attention deficit hyperactivity disorder (ADHD) rose slowly but steadily from 1996 to 2008, according to a study conducted by the National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ). The study was published online ahead of print September 28, 2011, in the American Journal of Psychiatry.
In a surprising reversal of long-standing scientific belief, researchers at the Mayo Clinic campus in Florida have discovered that inflammation in the brain is not the trigger that leads to buildup of amyloid deposits and development of Alzheimer's disease.
The experimental drug ibrutinib (PCI-32765) shows great promise for the treatment of elderly patients with chronic lymphocytic leukemia (CLL), according to interim findings from a clinical trial.
The newest guidelines for the use of cholesterol-lowering statins in people at risk of heart disease may be too generic, excluding middle-aged adults who could benefit from the drugs, and over-prescribing in older adults, according to a new study from the Duke Clinical Research Institute.
› Verified 4 days ago
| Entity Name | Mainegeneral Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669423380 PECOS PAC ID: 1254245715 Enrollment ID: O20031118000718 |
News Archive
A public-private consortium led by the biotech Iproteos -based at Parc Científic de Barcelona (PCB)-, and comprised by the biopharmaceutical company Ascil-Biopharma, the Institute for Biomedical Research (IRB Barcelona), the Centre for Genomic Regulation (CRG) and the University of the Basque Country (UPV/EHU) has launched a project to advance the development of a new neuroprotective drug for the treatment of the cognitive impairment associated with schizophrenia and other mental disorders.
The prescribed use of stimulant medications to treat attention deficit hyperactivity disorder (ADHD) rose slowly but steadily from 1996 to 2008, according to a study conducted by the National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ). The study was published online ahead of print September 28, 2011, in the American Journal of Psychiatry.
In a surprising reversal of long-standing scientific belief, researchers at the Mayo Clinic campus in Florida have discovered that inflammation in the brain is not the trigger that leads to buildup of amyloid deposits and development of Alzheimer's disease.
The experimental drug ibrutinib (PCI-32765) shows great promise for the treatment of elderly patients with chronic lymphocytic leukemia (CLL), according to interim findings from a clinical trial.
The newest guidelines for the use of cholesterol-lowering statins in people at risk of heart disease may be too generic, excluding middle-aged adults who could benefit from the drugs, and over-prescribing in older adults, according to a new study from the Duke Clinical Research Institute.
› Verified 4 days ago
| Entity Name | Eastern Maine Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790789147 PECOS PAC ID: 2062315161 Enrollment ID: O20040128000088 |
News Archive
A public-private consortium led by the biotech Iproteos -based at Parc Científic de Barcelona (PCB)-, and comprised by the biopharmaceutical company Ascil-Biopharma, the Institute for Biomedical Research (IRB Barcelona), the Centre for Genomic Regulation (CRG) and the University of the Basque Country (UPV/EHU) has launched a project to advance the development of a new neuroprotective drug for the treatment of the cognitive impairment associated with schizophrenia and other mental disorders.
The prescribed use of stimulant medications to treat attention deficit hyperactivity disorder (ADHD) rose slowly but steadily from 1996 to 2008, according to a study conducted by the National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ). The study was published online ahead of print September 28, 2011, in the American Journal of Psychiatry.
In a surprising reversal of long-standing scientific belief, researchers at the Mayo Clinic campus in Florida have discovered that inflammation in the brain is not the trigger that leads to buildup of amyloid deposits and development of Alzheimer's disease.
The experimental drug ibrutinib (PCI-32765) shows great promise for the treatment of elderly patients with chronic lymphocytic leukemia (CLL), according to interim findings from a clinical trial.
The newest guidelines for the use of cholesterol-lowering statins in people at risk of heart disease may be too generic, excluding middle-aged adults who could benefit from the drugs, and over-prescribing in older adults, according to a new study from the Duke Clinical Research Institute.
› Verified 4 days ago
| Entity Name | Mercy Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629078712 PECOS PAC ID: 6103737812 Enrollment ID: O20040217000943 |
News Archive
A public-private consortium led by the biotech Iproteos -based at Parc Científic de Barcelona (PCB)-, and comprised by the biopharmaceutical company Ascil-Biopharma, the Institute for Biomedical Research (IRB Barcelona), the Centre for Genomic Regulation (CRG) and the University of the Basque Country (UPV/EHU) has launched a project to advance the development of a new neuroprotective drug for the treatment of the cognitive impairment associated with schizophrenia and other mental disorders.
The prescribed use of stimulant medications to treat attention deficit hyperactivity disorder (ADHD) rose slowly but steadily from 1996 to 2008, according to a study conducted by the National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ). The study was published online ahead of print September 28, 2011, in the American Journal of Psychiatry.
In a surprising reversal of long-standing scientific belief, researchers at the Mayo Clinic campus in Florida have discovered that inflammation in the brain is not the trigger that leads to buildup of amyloid deposits and development of Alzheimer's disease.
The experimental drug ibrutinib (PCI-32765) shows great promise for the treatment of elderly patients with chronic lymphocytic leukemia (CLL), according to interim findings from a clinical trial.
The newest guidelines for the use of cholesterol-lowering statins in people at risk of heart disease may be too generic, excluding middle-aged adults who could benefit from the drugs, and over-prescribing in older adults, according to a new study from the Duke Clinical Research Institute.
› Verified 4 days ago
| Entity Name | St Marys Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447226584 PECOS PAC ID: 0042107120 Enrollment ID: O20040303000236 |
News Archive
A public-private consortium led by the biotech Iproteos -based at Parc Científic de Barcelona (PCB)-, and comprised by the biopharmaceutical company Ascil-Biopharma, the Institute for Biomedical Research (IRB Barcelona), the Centre for Genomic Regulation (CRG) and the University of the Basque Country (UPV/EHU) has launched a project to advance the development of a new neuroprotective drug for the treatment of the cognitive impairment associated with schizophrenia and other mental disorders.
The prescribed use of stimulant medications to treat attention deficit hyperactivity disorder (ADHD) rose slowly but steadily from 1996 to 2008, according to a study conducted by the National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ). The study was published online ahead of print September 28, 2011, in the American Journal of Psychiatry.
In a surprising reversal of long-standing scientific belief, researchers at the Mayo Clinic campus in Florida have discovered that inflammation in the brain is not the trigger that leads to buildup of amyloid deposits and development of Alzheimer's disease.
The experimental drug ibrutinib (PCI-32765) shows great promise for the treatment of elderly patients with chronic lymphocytic leukemia (CLL), according to interim findings from a clinical trial.
The newest guidelines for the use of cholesterol-lowering statins in people at risk of heart disease may be too generic, excluding middle-aged adults who could benefit from the drugs, and over-prescribing in older adults, according to a new study from the Duke Clinical Research Institute.
› Verified 4 days ago
| Entity Name | Central Maine Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689653487 PECOS PAC ID: 2567379563 Enrollment ID: O20040324000441 |
News Archive
A public-private consortium led by the biotech Iproteos -based at Parc Científic de Barcelona (PCB)-, and comprised by the biopharmaceutical company Ascil-Biopharma, the Institute for Biomedical Research (IRB Barcelona), the Centre for Genomic Regulation (CRG) and the University of the Basque Country (UPV/EHU) has launched a project to advance the development of a new neuroprotective drug for the treatment of the cognitive impairment associated with schizophrenia and other mental disorders.
The prescribed use of stimulant medications to treat attention deficit hyperactivity disorder (ADHD) rose slowly but steadily from 1996 to 2008, according to a study conducted by the National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ). The study was published online ahead of print September 28, 2011, in the American Journal of Psychiatry.
In a surprising reversal of long-standing scientific belief, researchers at the Mayo Clinic campus in Florida have discovered that inflammation in the brain is not the trigger that leads to buildup of amyloid deposits and development of Alzheimer's disease.
The experimental drug ibrutinib (PCI-32765) shows great promise for the treatment of elderly patients with chronic lymphocytic leukemia (CLL), according to interim findings from a clinical trial.
The newest guidelines for the use of cholesterol-lowering statins in people at risk of heart disease may be too generic, excluding middle-aged adults who could benefit from the drugs, and over-prescribing in older adults, according to a new study from the Duke Clinical Research Institute.
› Verified 4 days ago
| Entity Name | Maine Medical Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104921535 PECOS PAC ID: 9335043967 Enrollment ID: O20040331000274 |
News Archive
A public-private consortium led by the biotech Iproteos -based at Parc Científic de Barcelona (PCB)-, and comprised by the biopharmaceutical company Ascil-Biopharma, the Institute for Biomedical Research (IRB Barcelona), the Centre for Genomic Regulation (CRG) and the University of the Basque Country (UPV/EHU) has launched a project to advance the development of a new neuroprotective drug for the treatment of the cognitive impairment associated with schizophrenia and other mental disorders.
The prescribed use of stimulant medications to treat attention deficit hyperactivity disorder (ADHD) rose slowly but steadily from 1996 to 2008, according to a study conducted by the National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ). The study was published online ahead of print September 28, 2011, in the American Journal of Psychiatry.
In a surprising reversal of long-standing scientific belief, researchers at the Mayo Clinic campus in Florida have discovered that inflammation in the brain is not the trigger that leads to buildup of amyloid deposits and development of Alzheimer's disease.
The experimental drug ibrutinib (PCI-32765) shows great promise for the treatment of elderly patients with chronic lymphocytic leukemia (CLL), according to interim findings from a clinical trial.
The newest guidelines for the use of cholesterol-lowering statins in people at risk of heart disease may be too generic, excluding middle-aged adults who could benefit from the drugs, and over-prescribing in older adults, according to a new study from the Duke Clinical Research Institute.
› Verified 4 days ago
| Entity Name | Mainehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790265502 PECOS PAC ID: 7517860588 Enrollment ID: O20040701000166 |
News Archive
A public-private consortium led by the biotech Iproteos -based at Parc Científic de Barcelona (PCB)-, and comprised by the biopharmaceutical company Ascil-Biopharma, the Institute for Biomedical Research (IRB Barcelona), the Centre for Genomic Regulation (CRG) and the University of the Basque Country (UPV/EHU) has launched a project to advance the development of a new neuroprotective drug for the treatment of the cognitive impairment associated with schizophrenia and other mental disorders.
The prescribed use of stimulant medications to treat attention deficit hyperactivity disorder (ADHD) rose slowly but steadily from 1996 to 2008, according to a study conducted by the National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ). The study was published online ahead of print September 28, 2011, in the American Journal of Psychiatry.
In a surprising reversal of long-standing scientific belief, researchers at the Mayo Clinic campus in Florida have discovered that inflammation in the brain is not the trigger that leads to buildup of amyloid deposits and development of Alzheimer's disease.
The experimental drug ibrutinib (PCI-32765) shows great promise for the treatment of elderly patients with chronic lymphocytic leukemia (CLL), according to interim findings from a clinical trial.
The newest guidelines for the use of cholesterol-lowering statins in people at risk of heart disease may be too generic, excluding middle-aged adults who could benefit from the drugs, and over-prescribing in older adults, according to a new study from the Duke Clinical Research Institute.
› Verified 4 days ago
| Entity Name | Eastern Maine Healthcare Systems Inland Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376579557 PECOS PAC ID: 6305817503 Enrollment ID: O20040802001656 |
News Archive
A public-private consortium led by the biotech Iproteos -based at Parc Científic de Barcelona (PCB)-, and comprised by the biopharmaceutical company Ascil-Biopharma, the Institute for Biomedical Research (IRB Barcelona), the Centre for Genomic Regulation (CRG) and the University of the Basque Country (UPV/EHU) has launched a project to advance the development of a new neuroprotective drug for the treatment of the cognitive impairment associated with schizophrenia and other mental disorders.
The prescribed use of stimulant medications to treat attention deficit hyperactivity disorder (ADHD) rose slowly but steadily from 1996 to 2008, according to a study conducted by the National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ). The study was published online ahead of print September 28, 2011, in the American Journal of Psychiatry.
In a surprising reversal of long-standing scientific belief, researchers at the Mayo Clinic campus in Florida have discovered that inflammation in the brain is not the trigger that leads to buildup of amyloid deposits and development of Alzheimer's disease.
The experimental drug ibrutinib (PCI-32765) shows great promise for the treatment of elderly patients with chronic lymphocytic leukemia (CLL), according to interim findings from a clinical trial.
The newest guidelines for the use of cholesterol-lowering statins in people at risk of heart disease may be too generic, excluding middle-aged adults who could benefit from the drugs, and over-prescribing in older adults, according to a new study from the Duke Clinical Research Institute.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alexandria Mickenzie Betz, 100 N Academy Ave Dept Of, Danville, PA 17822-9800 Ph: (443) 722-3488 | Alexandria Mickenzie Betz, 887 Congress St Ste 200, Portland, ME 04102-3166 Ph: (207) 771-5549 |
News Archive
A public-private consortium led by the biotech Iproteos -based at Parc Científic de Barcelona (PCB)-, and comprised by the biopharmaceutical company Ascil-Biopharma, the Institute for Biomedical Research (IRB Barcelona), the Centre for Genomic Regulation (CRG) and the University of the Basque Country (UPV/EHU) has launched a project to advance the development of a new neuroprotective drug for the treatment of the cognitive impairment associated with schizophrenia and other mental disorders.
The prescribed use of stimulant medications to treat attention deficit hyperactivity disorder (ADHD) rose slowly but steadily from 1996 to 2008, according to a study conducted by the National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ). The study was published online ahead of print September 28, 2011, in the American Journal of Psychiatry.
In a surprising reversal of long-standing scientific belief, researchers at the Mayo Clinic campus in Florida have discovered that inflammation in the brain is not the trigger that leads to buildup of amyloid deposits and development of Alzheimer's disease.
The experimental drug ibrutinib (PCI-32765) shows great promise for the treatment of elderly patients with chronic lymphocytic leukemia (CLL), according to interim findings from a clinical trial.
The newest guidelines for the use of cholesterol-lowering statins in people at risk of heart disease may be too generic, excluding middle-aged adults who could benefit from the drugs, and over-prescribing in older adults, according to a new study from the Duke Clinical Research Institute.
› Verified 4 days ago
Carol M Vaughan, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 84 Marginal Way, Suite 900, Portland, ME 04101 Phone: 207-874-2445 Fax: 207-523-8598 | |
Toby M Fitzgerald, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 887 Congress St Ste 200, Portland, ME 04102 Phone: 207-771-5549 Fax: 207-771-7834 | |
Dr. Edward Bumno Yoon, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 895 Washington Ave, Portland, ME 04103 Phone: 207-791-3888 | |
Dr. Kathryn G Wadland, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 195 Fore River Pkwy, Suite 440, Portland, ME 04102 Phone: 207-553-6920 Fax: 207-553-6940 | |
Anne Marie Van Hengel, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 84 Marginal Way, Suite 900, Portland, ME 04101 Phone: 207-874-2445 Fax: 207-523-8598 | |
Dr. Debra K Sepulveda, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-0111 Fax: 207-662-6219 | |
Mary Anne Carroll, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: Maine Medical Center, 22 Bramhall Street, Portland, ME 04102 Phone: 207-662-0111 |